Stingray Therapeutics
Stingray Therapeutics is a clinical stage biotech company focused on developing next-generation immune therapies to combat cancer. Their revolutionary approach enables the full immune system to fight back against cancer, targeting innate immunity checkpoint ENPP1 to enhance immune response and reduce tumor resistance.
Industries
biotechnology
health-care
therapeutics
Nr. of Employees
small (1-50)
Products
Clinical-stage ENPP1-targeting immunotherapy candidate(s)
Therapeutic candidates developed to inhibit ENPP1 and reactivate innate immune signaling (cGAS–STING pathway) in tumors; development includes small-molecule inhibitor programs and clinical-stage immunotherapy efforts.
Clinical-stage ENPP1-targeting immunotherapy candidate(s)
Therapeutic candidates developed to inhibit ENPP1 and reactivate innate immune signaling (cGAS–STING pathway) in tumors; development includes small-molecule inhibitor programs and clinical-stage immunotherapy efforts.
Services
Collaborative preclinical development and testing
Partnership-based preclinical development and testing of oncology therapeutic candidates in collaboration with external research institutes.
Collaborative preclinical development and testing
Partnership-based preclinical development and testing of oncology therapeutic candidates in collaboration with external research institutes.
Expertise Areas
- Immunotherapy development
- Cancer drug discovery (ENPP1-focused)
- Preclinical and translational research
- Clinical trial operations and management
Key Technologies
- ENPP1 inhibition
- cGAS–STING pathway assays
- Small-molecule medicinal chemistry
- Oral small-molecule candidate development